Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336344 | 1.00 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL21649720 | 0.91 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22746497 | 0.91 | GAA (0.46) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL25778035 | 0.91 | NAMPT (0.38) | — | |
| SCHEMBL22854052 | 0.88 | GAA (0.45) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22854024 | 0.88 | GAA (0.45) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL26445322 | 0.87 | GAA (0.44) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22336359 | 0.84 | GAA (0.41) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22746401 | 0.84 | GAA (0.41) | GAAMAPTCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL24869079 | 0.83 | MEN1 (0.40) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220177578-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20200407440-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MAGENTA THERAPEUTICS INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177575-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | GAA 779/4885MAPT 4561/4885CRHBP 4278/4885 |
| US-20200407440-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MYADM, FUT7, SIGLEC7 | GAA 572/4885MAPT 3537/4885CRHBP 4038/4885 |
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD40LG, CD44, CD74 | GAA 732/4885MAPT 3019/4885CRHBP 1738/4885 |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | GAA 1194/4885MAPT 4451/4885CRHBP 4103/4885 |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD44, LY6K, CD2 | GAA 351/4885MAPT 2706/4885CRHBP 3970/4885 |
| US-20220177578-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | GAA 779/4885MAPT 4561/4885CRHBP 4278/4885 |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | GAA 1194/4885MAPT 4451/4885CRHBP 4103/4885 |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | CD2, CD4, CD22 | GAA 3378/4885MAPT 2378/4885CRHBP 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.